Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
EMERYVILLE, Calif., May 31, 2017 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Michael P. Smith, Executive Vice President, Chief Financial Officer & Treasurer and Secretary, will present a corporate overview at the Jefferies 2017 Global Healthcare Conference, taking place on June 6-9, 2017, in New York, NY.
Zogenix Presentation Details
| Date: | Wednesday, June 7, 2017 |
| Time: | 2:00 pm Eastern Time / 11:00 am Pacific Time |
The presentation will be webcast live and archived for 30 days on Zogenix's Investor Relations website at ir.zogenix.com.
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT: Investors: Andrew McDonald Founding Partner, LifeSci Advisors LLC 646-597-6987 | [email protected]
